Lv6
1969 积分 2023-03-30 加入
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
8天前
已完结
Invasive candidiasis
9天前
已关闭
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial
11天前
已完结
A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma
15天前
已完结
Combining Bioactive Cell-Penetrating Peptides and Vemurafenib to Produce Peptide–Drug Conjugates with Activity Against Drug-Resistant Melanoma Cells
18天前
已完结
A molecular glue halts RAS–MAPK signaling
21天前
已完结
The MEK–RAF molecular glue IK-595 has potent antitumor activity across RAS/MAPK pathway-altered cancers
22天前
已完结
Pan-RAF:MEK Molecular Glues Take Center Stage
22天前
已完结
MEK inhibitors loosen RAF’s grip
22天前
已关闭
Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
23天前
已完结
皖公网安备34019202002308
